Patents by Inventor David Porubek

David Porubek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060211713
    Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.
    Type: Application
    Filed: March 8, 2006
    Publication date: September 21, 2006
    Inventors: David Porubek, Anil Kumar, Charles Bredl, J. Klein
  • Patent number: 7053096
    Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.
    Type: Grant
    Filed: May 5, 2004
    Date of Patent: May 30, 2006
    Assignee: Cell Therapeutics Inc.
    Inventors: David Porubek, Anil M. Kumar, Charles R. Bredl, J. Peter Klein
  • Publication number: 20040229836
    Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.
    Type: Application
    Filed: May 5, 2004
    Publication date: November 18, 2004
    Applicant: CELL THERAPEUTICS, INC.
    Inventors: David Porubek, Anil M. Kumar, Charles R. Bredl, J. Peter Klein
  • Patent number: 6780865
    Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.
    Type: Grant
    Filed: September 18, 1997
    Date of Patent: August 24, 2004
    Assignee: Cell Therapeutics, Inc.
    Inventors: David Porubek, Anil M. Kumar, Charles R. Bredl, J. Peter Klein
  • Patent number: 6693105
    Abstract: Disclosed are therapeutic compounds having the formula: (R)j—(CORE MOIETY), including resolved enantiomers, diastereomers, hydrates, salts, solvates or mixtures thereof where j is an integer from one to three. The core moiety is a bicyclic ring structure having at least one heterocyclic ring that contains five to six ring atoms and up to two nitrogen heteroatoms. R is selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C1-6 alkyl or C1-6 alkenyl, and at least one R has the formula I: n is an integer from 1 to 20, at least one of X or Y is —OH. Another of X or Y, which is not —OH, is hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2—or (CH3)2—CH2—, and each W1, W2, and W3 is independently hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2— or (CH3)2—CH2—.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: February 17, 2004
    Assignee: Cell Therapeutics, Inc.
    Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson, Stephen J. Klaus, Anil M. Kumar, John Tulinsky
  • Publication number: 20030207901
    Abstract: Disclosed are therapeutic compounds having the formula:
    Type: Application
    Filed: May 14, 2003
    Publication date: November 6, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson, Stephen J. Klaus, Anil M. Kumar, John Tulinsky
  • Patent number: 6133274
    Abstract: Disclosed are therapeutic compounds having the formula:(R)j-(core moiety),including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.
    Type: Grant
    Filed: November 26, 1996
    Date of Patent: October 17, 2000
    Assignee: Cell Therapeutics, Inc.
    Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson
  • Patent number: 5965564
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: October 12, 1999
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5804584
    Abstract: Disclosed are therapeutic compounds having the formula:(R)j-(core moiety),including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 8, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson
  • Patent number: 5792772
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: August 11, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5780476
    Abstract: Disclosed are therapeutic compounds having the formula:(R)j - (core moiety),including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 14, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson
  • Patent number: 5739138
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 14, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5648357
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: July 15, 1997
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5629315
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: May 13, 1997
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5620984
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating inflammatory disease.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 15, 1997
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5621102
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 15, 1997
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5612349
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: March 18, 1997
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5580873
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating proliferative vascular disease.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: December 3, 1996
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5580874
    Abstract: Them is disclosed compounds and pharmaceutical compositions that is R enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating the side effects of immunosuppressive agent and interleukin-2 therapy.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: December 3, 1996
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5567704
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating baldness.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: October 22, 1996
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer